Protein Biomarkers in Risk and Prognosis of Amyotrophic Lateral Sclerosis

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.

ALS phenotype is influenced by age, sex, and genetics A population-based study

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate.

Special Issue “Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders”

Central nervous system (CNS) diseases and disorders have posed a substantial challenge to global health, contributing to disability, mortality, and healthcare costs [...].

Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment

The role of complement in Alzheimer's disease (AD) remains unclear, particularly regarding tau pathology and memory decline.

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.